tbuckley/cabot-search huggingface dataset:
Compact Molecular Conformation of Prodrugs Enhances Photocleaving Performance for Tumor Vascular Growth Inhibition
Authors: Wen‐Yue Lin, Hui‐Ping Wen, Jia‐Yao Li, Juan‐Mei Wang, Hong‐Juan Feng, Zhi Huang, Ran Li, Le Zeng, Ling Huang
Journal: Advanced Healthcare Materials (2024)

Highly spatiotemporal-resolved photomodulation demonstrates promise for investigating key biological events in vivo and in vitro, such as cell signaling pathways, neuromodulation, and tumor treatment without side effects. However, enhancing the performance of photomodulation tools remains challenging due to the limitations of the physicochemical properties of the photoactive molecules. Here, a compact, stable intramolecular π-π stacking conformation forming between the target molecule (naproxen) and the perylene-based photoremovable protecting group is discovered to confine the motion of the photolabile bond and then enhance the photocleavage quantum yield. In conjunction with a red-absorbing photosensitizer, the photocleavage wavelength is extended to the red region via triplet-triplet annihilation. In particular, the triplet lifetime of the prodrug can be extended via the linked steric hindrance to improve the conversion yield via TTA. Using the new photomodulation tool, it is precisely photoreleased cyclooxygenase-2 inhibitors for tumor vascular growth suppression in vivo. In combination with cisplatin, over 90% efficient inhibition of malignant breast tumors is observed via the synergistic tumor treatment strategy. These findings provide a new concept for the rational design of efficient photocleavage and have implications for photomodulating cell signaling pathways in tumor therapy, as well as laying a solid foundation for the development of phototherapeutic approaches.
Aptamer‐Encapsulated Cellular Nanoparticles for Neurotoxin Neutralization
Authors: Mingxuan Kai, Wei‐Ting Shen, Dan Wang, Yiyan Yu, Jiayuan Alex Zhang, Lei Sun, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang
Journal: Advanced Healthcare Materials (2024)

Abstract Aptamers are single‐stranded oligonucleotides that fold into defined architectures for specific target binding. In this study, aptamers are selected that specifically bind to small‐molecule neurotoxins and encapsulate them into cell membrane‐coated nanoparticles (referred to as ‘cellular nanoparticles’ or ‘CNPs’) for effective neutralization of neurotoxins. Specifically, six different aptamers are selected that bind to saxitoxin (STX) or tetrodotoxin (TTX) and encapsulate them into metal–organic framework cores, which are then coated with neuronal cell membrane. The resulting CNPs exhibit high colloidal stability, minimal aptamer leakage, and effective protection of aptamer payloads against enzyme degradation. This detoxification platform combines membrane‐enabled broad‐spectrum neutralization with aptamer‐based specific toxin binding, offering dual‐modal neutralization mechanisms for efficient neurotoxin neutralization. The in vitro neutralization efficacy is demonstrated using a neuron osmotic swelling assay, a Na + flux fluorescence assay, and a cytotoxicity assay. The in vivo neutralization efficacy is further validated using mouse models of STX and TTX intoxication in both therapeutic and preventative regimens. Overall, integrating aptamers with CNPs combines the strengths of both technologies, resulting in a robust solution for broad‐spectrum toxin‐neutralization applications.
Bacterial Responses and Material‐Cell Interplays With Novel MoAlB@MBene
Authors: Michał Jakubczak, Dominika Bury, Verónica Montes‐García, Artur Ciesielski, Michael Naguib, Agnieszka M. Jastrzębska
Journal: Advanced Healthcare Materials (2024)

Abstract Developing efficient antibacterial nanomaterials has potential across diverse fields, but it requires a deeper understanding of material‐bacteria interactions. In this study, a novel 2D core‐shell MoAlB@MBene structure is synthesized using a mild wet‐chemical etching approach. The growth of E. coli , S. aureus , and B. subtilis bacteria in the presence of MoAlB@MBene decreased in a concentration‐dependent manner, with a prolonged lag phase in the initial 6 h of incubation. Even under dark conditions, MoAlB@MBene triggered the formation of intercellular reactive oxygen species (ROS) and singlet oxygen ( 1 O 2 ) in bacteria, while the bacteria protected themselves by forming biofilm and altering cell morphology. The MoAlB@MBene shows consistent light absorption across the visible range, along with a distinctive UV absorption edge. Two types of band gaps are identified: direct (1.67 eV) and indirect (0.74 eV), which facilitate complex light interactions with MoAlB@MBene. Exposure to simulated white light led to decreased viability rates of E. coli (20.6%), S. aureus (22.9%), and B. subtilis (21.4%). Altogether, the presented study enhances the understanding of bacteria responses in the presence of light‐activated 2D nanomaterials.
A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Authors: Erin M. Euliano, Brett H. Pogostin, Anushka Agrawal, Marina H. Yu, Tsvetelina H. Baryakova, Tyler P. Graf, Alyssa A. Kunkel, Kiana A. Cahue, Jeffrey D. Hartgerink, Kevin J. McHugh
Journal: Advanced Healthcare Materials (2024)

Abstract Toll‐like receptors (TLRs) recognize pathogen‐ and damage‐associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants. Many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co‐localization with antigens and, thus, their effect. Here, the small‐molecule TLR7 agonist 1V209 is conjugated to a positively‐charged multidomain peptide (MDP) hydrogel, K 2 , which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209‐conjugated K 2 50:50 with the unfunctionalized K 2 produces hydrogels that retain the shear‐thinning and self‐healing physical properties of the original MDP while improving the solubility of 1V209 more than 200‐fold compared to the unconjugated molecule. When co‐delivered with ovalbumin as a model antigen, 1V209‐functionalized K 2 produces a robust Th2 immune response and an antigen‐specific Th1 immune response superior to alum, a widely used vaccine adjuvant. Together, these results suggest that K 2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response.
From bite to brain: Neuro‐immune interactions in food allergy
Authors: Vikki Houghton, Thomas Eiwegger, Esther Borges Florsheim, Rebecca C. Knibb, Sandrine Thuret, Alexandra F. Santos
Journal: Allergy (2024)

Abstract Immunoglobulin E (IgE)‐mediated food allergies are reported to affect around 3.5% of children and 2.4% of adults, with symptoms varying in range and severity. While being the gold standard for diagnosis, oral food challenges are burdensome, and diagnostic tools based on specific IgE can be flawed. Furthering our understanding of the mechanisms behind food allergy onset, severity and persistence could help reveal immune profiles associated with the disease, to ultimately aid in diagnosis. Alterations to cytokine levels and immune cell ratios have been identified, though further research is needed to fully capture the heterogenous nature of food allergy. Moreover, the existence of such immune alterations also raises the question of potential wider systemic effects. For example, recent research has emphasised the existence and impact of neuro‐immune interactions and implicated behavioural and neurological changes associated with food allergy. This review will provide an overview of such food allergy‐driven neuro‐immune interactions, with the aim of emphasising the importance of furthering our understanding of the immune mechanisms underlying IgE‐mediated food allergy.
Progranulin derivative attenuates lung neutrophilic infiltration from diesel exhaust particle exposure
Authors: A. Ryang Lee, Mini Jeong, Kyomoon Koo, Sin‐Jeong Kim, Min Ju Pyo, Yeeun Hong, Yura Ha, Keun‐Ai Moon, Hyun Jae Shim, Ji‐Hyang Lee, Hyouk‐Soo Kwon, You Sook Cho
Journal: Allergy (2024)

Abstract Background Air pollutants, such as diesel exhaust particles (DEPs), induce respiratory disease exacerbation with neutrophilic infiltration. Progranulin (PGRN), an epithelial cell and macrophage‐derived secretory protein, is associated with neutrophilic inflammation. PGRN is digested into various derivatives at inflammatory sites and is involved in several inflammatory processes. PGRN and its derivatives likely regulate responses to DEP exposure in allergic airway inflammation. Aim To investigate the role of PGRN and its derivatives in the regulation of responses to DEP exposure in allergic airway inflammation. Methods A murine model of allergic airway inflammation was generated in PGRN‐deficient mice, and they were simultaneously exposed to DEP followed by intranasal administration of full‐length recombinant PGRN (PGRN‐FL) and a PGRN‐derived fragment (FBAC). Inflammatory status was evaluated by bronchoalveolar lavage fluid and histopathologic analyses. Human bronchial epithelial cells were stimulated with DEPs and house dust mites (HDMs), and the effect of FBAC treatment was evaluated by assessing various intracellular signaling molecules, autophagy markers, inflammatory cytokines, and intracellular oxidative stress. Results DEP exposure exaggerated neutrophilic inflammation, enhanced IL‐6 and CXCL15 secretions, and increased oxidative stress in the murine model; this effect was greater in PGRN‐deficient mice than in wild‐type mice. The DEP‐exposed mice with PGRN‐FL treatment revealed no change in neutrophil infiltration and higher oxidative stress status in the lungs. On the contrary, FBAC administration inhibited neutrophilic infiltration and reduced oxidative stress. In human bronchial epithelial cells, DEP and HDM exposure increased intracellular oxidative stress and IL‐6 and IL‐8 secretion. Decreased nuclear factor erythroid 2‐related factor 2 (Nrf2) expression and increased phosphor‐p62 and LC3B expression were also observed. FBAC treatment attenuated oxidative stress from DEP and HDM exposure. Conclusions FBAC reduced neutrophilic inflammation exaggerated by DEP exposure in a mouse model of allergic airway inflammation by reducing oxidative stress. PGRN and PGRN‐derived proteins may be novel therapeutic agents in attenuating asthma exacerbation induced by air pollutant exposure.
Blocking the <scp>HIF</scp>‐1α/glycolysis axis inhibits allergic airway inflammation by reducing <scp>ILC2</scp> metabolism and function
Authors: Xiaogang Zhang, Jingping Liu, Xinyao Li, Guilang Zheng, Tianci Wang, Hengbiao Sun, Zhengcong Huang, Junyu He, Ju Qiu, Zhibin Zhao, Yuxiong Guo, Yumei He
Journal: Allergy (2024)

Abstract Background The role of lung group 2 innate lymphoid cell (ILC2) activation in allergic asthma is increasingly established. However, the regulatory mechanisms underlying hypoxia‐inducible factor‐1α (HIF‐1α)‐mediated glycolysis in ILC2‐mediated allergic airway inflammation remain unclear. Objective To investigate the role of the HIF‐1α/glycolysis axis in ILC2‐mediated allergic airway inflammation. Methods Glycolysis and HIF‐1α inhibitors were used to identify their effect on the function and glucose metabolism of mouse and human ILC2s in vivo and vitro. Blocking glycolysis and HIF‐1α in mice under interleukin‐33 (IL‐33) stimulation were performed to test ILC2 responses. Conditional HIF‐1α‐deficient mice were used to confirm the specific role of HIF‐1α in ILC2‐driven airway inflammation models. Transcriptomic, metabolic, and chromatin immunoprecipitation analyses were performed to elucidate the underlying mechanism. Results HIF‐1α is involved in ILC2 metabolism and is crucial in allergic airway inflammation. Single‐cell sequencing data analysis and qPCR confirmation revealed a significant upregulation of glycolysis‐related genes, particularly HIF‐1α, in murine lung ILC2s after IL‐33 intranasal administration or injection. Treatment with the glycolysis inhibitor 2‐deoxy‐D‐glucose (2‐DG) and the HIF‐1α inhibitor 2‐methoxyestradiol (2‐ME) abrogated inflammation by suppressing ILC2s function. Conditional HIF‐1α‐deficient mice showed reduced ILC2 response and airway inflammation induced upon IL‐33 or house dust mite (HDM) stimulation. Transcriptome and metabolic analyses revealed significantly impaired glycolysis in lung ILC2s in conditional HIF‐1α knockout mice compared to that in their littermate controls. Chromatin immunoprecipitation results confirmed the transcriptional downregulation of glycolysis‐related genes in HIF‐1α‐knockout and 2‐DG‐treated mice. Furthermore, impaired HIF‐1α/glycolysis axis activation is correlated with downregulated ILC2 in patients with asthma. Conclusion The HIF‐1α/glycolysis axis is critical for controlling ILC2 responses in allergic airway inflammation and has potential immunotherapeutic value in asthma.
Evidence for Mechanical Circulatory Support in Cardiogenic Shock
Authors: Jason E. Bloom, Kais Hyasat, Ajay J. Kirtane
Journal: JAMA Cardiology (2024)

Nanna Louise Junker Udesen, MD, PhD; Rasmus Paulin Beske, MD; Christian Hassager, MD, DMSc; Lisette Okkels Jensen, MD, PhD, DMSc; Hans Eiskjær, DMSc; Norman Mangner, DrMed; Amin Polzin, DrMed; P. Christian Schulze, DrMed; Carsten Skurk, DrMed; Peter Nordbeck, DrMed; Peter Clemmensen, MD, DMSc; Vasileios Panoulas, MD; Sebastian Zimmer, DrMed; Andreas Schäfer, DrMed; Nikos Werner, DrMed; Martin Frydland, PhD; Lene Holmvang, MD, DmSc; Jesper Kjærgaard, MD, PhD, DMSc; Thomas Engstøm, MD, DMSc; Henrik Schmidt, MD, DMSc; Anders Junker, MD, PhD; Christian Juhl Terkelsen, MD, PhD, DMSc; Steffen Christensen, MD, PhD; Axel Linke, DrMed; Jacob Eifer Møller, MD, PhD, DMsc; DanGer Shock Investigators; Matias G Lindholm; Jacob T Lønborg; Søren Boesgaard; Rikke Sørensen; Kristian Wachtell; Hanne B Ravn; Jens F Lassen; Karsten T Veien; Evald H Christiansen; Felix J Woitek; Jennifer Hommel; Sven Moebius-Winkler; Inge De Haas; Ralf Westenfeld
P3-3 Progression-free survival and overall survival of pembrolizumab for patients with esophageal cancer: a meta-analysis
Authors: K. Aurelia Santoso, S. Kosayuz, W. Surya Atmaja, A. Irviani Ukhti Amalia, D. Ravinder Theodeus Subroto, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P39-4 Evaluating the efficacy of lorlatinib versus crizotinib in ALK-positive lung cancer patients: a systematic review
Authors: W.W. Sito, G.L. Triaswhoro, C. Arivia, F. Sidharta, W. Atmadji, C. Angelius, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P37-4 Efficacy and toxicity of pemetrexed and cisplatin in early stage non-small cell lung cancer: a systematic review of RCTs
Authors: M. Gracia Kumala, M.A.W. Hutapea, V.K.C. Chan, C.E. Tjipto, F. Wulandari, J.A. Liem, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P65-1 Safety and pharmacokinetics (PK) of TAR-210 in Japanese with bladder cancer and select FGFR alterations: phase 1 study
Authors: K. Nishimura, T. Kimura, E. Kikuchi, H. Kitamura, S. Hashibe, M. Mukai, E. Fujikawa, T. Ote
Journal: Annals of Oncology (2024)
P85-2 Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
Authors: C.C. Arenos, M. San Juan, S. Lim, A. Lominoque, I. Reveldez, A. Sison-DImaano, N. Pangandaman, V. Tatoy, T. Uy
Journal: Annals of Oncology (2024)
Effects of dialysate potassium concentration of 3.0mEq/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0mEq/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia
Authors: David M Charytan, Wolfgang C Winkelmayer, Christopher B Granger, John P Middleton, Charles A Herzog, Glenn M Chertow, James M Eudicone, Jeremy D Whitson, James A Tumlin
Journal: Kidney International (2024)
P65-4 PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
Authors: W. Binti Wan Ishak, S. Cheong, I. Muhamad Nor, B. Selvam, G. Ho, C. Tan, Y. Wong, P. Kue, A. Wai, A. Yahya
Journal: Annals of Oncology (2024)
P81-4 Nivolumab-related myositis, myocarditis and cytokine release syndrome: a case report
Authors: Q. Phamnguyen, Y. Shikata, K. Matsuda, A. Suzuki, S. Kataoka, A. Nozaki, N. Tanaka, C. Kinoshita, M. Tanaka, Y. Ogino, T. Kobayashi, K. Yamashita, Y. Inoue
Journal: Annals of Oncology (2024)
P9-4 Experiences with trastuzumab deruxtecan in 11 cases of advanced gastric cancer
Authors: H. Yamane, Y. Sugiyama, T. Komo, N. Miyashige, K. Shibata, S. Tahara, H. Otsuka, T. Yamaguchi, T. Tazaki, M. Kouyama, A. Nakamitsu, M. Sasaki
Journal: Annals of Oncology (2024)
P89-1 Comparative effectiveness of T-DM1 and T-DXd in the treatment of metastatic breast cancer: a systematic review of RCTs
Authors: H. Angelita, S. Sharanya, A.O.M. Sinaga, G.A. Putriasari, S.C. Sutrisno, C.F. Jhoputri, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P64-3 Why are protocol-related queries in Japan remarkably increased compared to other regions? Survey targeting CRCs and CRAs
Authors: Y. Kondo, Y. Izumi, H. Sasamoto, X. Qiu, M. Omae, A. Oura, S. Takahara, A. Nozaki, T. Tsuda, K. Ando, T. Takeuchi, T. Matsuda, S. Kobayashi, Y. Maruyama, S. Okawa, K. Inoue, H. Aono, S. Washio, J. Shinagawa
Journal: Annals of Oncology (2024)
P57-8 The efficacy and safety of lenvatinib on patients with hepatocellular carcinoma: a systematic review of RCTs
Authors: M.H. Wibisono, A.D. Nansito, E. Marson, R. Revaldo, W.S. Li, E. Vinsky, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P85-7 PARP inhibitors and chemotherapy in breast cancer patients with BRCA-1 or BRCA-2 gene mutations: a systematic review
Authors: C. Arivia, F. Sidharta, G. Lintang Triaswhoro, W. Atmadji, W. Winston Sito, C. Angelius, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P65-6 Efficacy and safety of acupuncture in breast cancer patients with taxane-induced peripheral neurotoxicity
Authors: H. Ishiki, E. Satomi, H. Matsuoka, S. Arakawa, N. Kawasaki, Y. Horiguchi, A. Takahashi, T. Murata, A. Suto
Journal: Annals of Oncology (2024)
P41-6 The toxicity profile of durvalumab leading to interruption for stage III non-small cell lung cancer in clinical practice
Authors: T. Teshirogi, H. Izumi, T. Sakai, H. Udagawa, E. Sugiyama, Y. Zenke, S. Umemura, S. Matsumoto, K. Yoh, K. Goto
Journal: Annals of Oncology (2024)
P20-1 Photodynamic-controllable smart delivery of combined PARP inhibitor with natural nanoparticles for anticancer treatment
Authors: A. Onggarbek, G. Nazarbek, Z. Omarova, A. Shaimoldina, Z. Bauyrzhanova, A. Orassay, V. Milov, A. Onggarbek, H. Fan, N. Toktarov, A. Amin, Z. Chen, Y. Xie
Journal: Annals of Oncology (2024)
P49-2 Feasibility and safety of exercise in rectal cancer during chemoradiation: a systematic review
Authors: E.C.K. Sucahyo, C.L. Kong, L. Julian, N.D.D. Rustiadi, A.M. Susanto, M.Z. Sabran, J.A. Liem, F. Wijovi, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P6-7 Sorafenib maintenance post-allogeneic HCT in reducing relapse of patients with FLT3-ITD AML: a systematic review
Authors: G.L. Triaswhoro, W.W. Sito, C. Arivia, F. Sidharta, W. Atmadji, C. Angelius, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P11-3 Efficay and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites
Authors: T. Matsumoto, C. Makiyama, A. Nakasya, H. Nagai, T. Ikoma, T. Yasuda, S. Boku, N. Shibata, T. Tsuduki, H. Yasui, H. Satake
Journal: Annals of Oncology (2024)
P42-2 Systematic review of pembrolizumab vs. chemotherapy in PD-L1-positive advanced NSCLC as first line of treatment
Authors: W. Atmadji, C. Arivia, F. Sidharta, G. Lintang Triaswhoro, W. Winston Sito, C. Angelius, I. Huang, A. Kurniawan
Journal: Annals of Oncology (2024)
P90-6 Efficacy and safety of neratinib and capecitabine in HER2-positive metastatic breast cancer: a systematic review
Authors: E. Wilhelmina Mokalu, M. Zuhriansyah Sabran, P. Yossy, K. Yogasvara Rubismo, A. Zebua, N. Albert, J. Irisha Xenia Hasan, A. Kurniawan
Journal: Annals of Oncology (2024)
P27-3 Report of the cancer salon at Jichi Medical University Hospital – the 9th report
Authors: R. Yamamoto, Y. Kojima, Y. Oeda, K. Minagawa, M. Inada, M. Inoue, M. Kameda, S. Chiba, Y. Okuda, Y. Izuka, K. Sato, K. Komatsuzaki, A. Nakayama, H. Yamaguchi
Journal: Annals of Oncology (2024)
P37-1 A diagnostic nomogram for pathological invasiveness in early LUAD: integration of autoantibody and radiomics features
Authors: Z. Gao, W. Yu, S. Huang, S. Wang, R. Chen, Y. Tang, X. Ben, J. Tang, D. Zhang, L. Xie, H. Zhou, G. Chen, G. Qiao
Journal: Annals of Oncology (2024)
P66-3 Questionnaire survey on technical support for the research project on practical research for innovative cancer control
Authors: Y. Sano, M. Jinno, T. Morita, S. Sekiya, S. Ishibashi, K. Miura, Y. Ikarashi, K. Aoyagi, F. Takeshita, A. Hamada
Journal: Annals of Oncology (2024)
P27-1 Psychological readiness for salvage chemotherapy: adult patients with hematological malignancies who have first relapsed
Authors: K. Akashi, Y. Imai, S. Nakamura, Y. Maeda, R. Sumitani, M. Oura, K. Sogabe, M. Takahashi, S. Fujii, T. Harada, H. Miki
Journal: Annals of Oncology (2024)
P4-5 Patient characteristics and treatment patterns in patients with Mantle cell lymphoma in Japan: a real-world study
Authors: S. Rai, Y. Tanizawa, T. Terasawa, M. Tajimi, R. Ideue, H. Burlison, N. Milloy, B. Goebel, A. Kiran
Journal: Annals of Oncology (2024)
P4-2 Efficacy and safety of chimeric antigen receptor-T cells in B cell lymphoma malignacy: a systematic review meta-analysis
Authors: A. Kurniawan, F. Wijovi, P. Angel, D. Priantono, C. Sari, D. Astri Rivera Amelia, D. Djatnika, M. Arman Nasution, N. Prasasti Purlikasari, F. Ariyanti, B. Agustia Wisman, R. Kurniawan, J. Sinurat, A. Ardian, G. Chandra Kirana Sugianto, N. Novianti Siregar, N. Merlynda P Dewi
Journal: Annals of Oncology (2024)
P21-3 A pilot study on miRNA detection in residual of liquid-based high-risk genotype HPV samples for ovarian cancer diagnosis
Authors: E.S.M. Chu, R.W.K. Wu, T. Chiu, L.K.N. Cheung, A.Y.Y. Kong, O.C.K. Ma, J.S.K. Lee
Journal: Annals of Oncology (2024)
P35-1 The impact of COVID-19 pandemic on psychological well-being of oncology healthcare providers in Malaysia
Authors: N. Zainal, W. Wan Ishak, C. Ng, A. Roslani, G. Gan, W. Wong, M. Isa, N. Bhoo Pathy, Y. Woo, M. Abu Bakar, R. Mohamaed, S. Ab. Rahman
Journal: Annals of Oncology (2024)
P4-3 An experience of pola-R-CHP regimen for DLBCL patients at our hospital
Authors: T. Takahata, E. Sato, T. Tsurumoto, S. Yamashita, T. Ebina, T. Tachita, K. Kamata, K. Yamagata, Y. Tamai, H. Sakuraba
Journal: Annals of Oncology (2024)
P16-3 Total skin electron beam therapy (TSEBT) for mycosis fungoides: the first CARE-compliant reports from Indonesia
Authors: A. Prawira Putra, C. Kotambunan, A. Rahma Fauzia, W. Edy Wibowo, A. Giselvania, A. Munandar, I. Ramli
Journal: Annals of Oncology (2024)
P21-8 Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment
Authors: H. Pan, L. Keller, I. Heidrich, J. Kott, C.W. Abbott, S. Boyle, J. Pugh, R.O. Chen, G. Geidel, S. Ronald, S. Schneider, C. Gebhardt, K. Pantel
Journal: Annals of Oncology (2024)
Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials
Authors: Robin W M Vernooij, Carinna Hockham, Giovanni Strippoli, Suetonia Green, Jörgen Hegbrant, Andrew Davenport, Claudia Barth, Bernard Canaud, Mark Woodward, Peter J Blankestijn, Michiel L Bots
Journal: The Lancet (2024)
P87-9 Effect of pembrolizumab as neoadjuvant therapy in early triple-negative breast cancer: a systematic review
Authors: R.V. Sunaryo, C.P. Meta, Z. Amelia, S. Harahap, M. Briegetta, C.F. Jhoputri, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)